Mapp Biopharmaceutical

Mapp Biopharmaceutical, Inc. “Mapp” is a San Diego based, innovative biopharmaceutical company focused on addressing unmet medical needs through the development of life-saving monoclonal antibody treatment options to combat a variety of neglected and tropical infectious diseases.  Mapp was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin and has been developing an Ebola therapy for more than a decade.

As these products transition to clinical evaluation, LeafBio assumes ownership and commercialization responsibilities.